Although the methylation status of the O6-methylguanine-DNA methyltransferase (MGMT) promoter is considered a useful biomarker for predicting outcomes and guiding treatment decisions in glioma, its actual value in this regard is still a subject of debate. The gene discussed is MGMT; the disease is central nervous system cancer.